View
Page
"Chi-Med has announced the initiation of a Phase II expansion of the ongoing TATTON trial (NCT02143466) to evaluate the selective c-Met inhibitor savolitinib (AZD6094) in EGFR mutant non-small cell lung cancer (NSCLC) patients. The announced initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med." Panmure note out this morning on Research Tree
Welcome to the new Hutchison China Meditech stream forum! Messages posted in the Hutchison China Meditech stream will be logged here for posterity.
Latest from the Community...
Latest from the Community...
Latest from the Community...